Desai Chirag, Mehta Anurag, Mishra Divya
Department of Hemato-Oncology Clinic, Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India.
Department of Pathology, Rajiv Gandhi Cancer Institute, New Delhi, India.
Lung India. 2014 Jul;31(3):249-59. doi: 10.4103/0970-2113.135767.
Personalized medicine has facilitated improved management of non-small cell lung cancer (NSCLC) patients by identifying predictive and prognostic biomarkers for enhanced efficiency of detection and efficacy of treatment. This systematic review and survey assessed the patterns of biomarker usage, molecular testing techniques to diagnose patients with NSCLC in India and testing techniques recommended by cancer societies.
Studies were retrieved from Embase, PubMed, and Cochrane databases for the last 12 years, using relevant search strategies as per the Cochrane methodology for systematic reviews. Outcomes of interest were biomarkers for NSCLC, patterns of biomarker testing, diagnostic methods, guidelines and cost of biomarker testing.
In all, 499 studies were identified for screening and 17 primary publications were included in the review. Epidermal growth factor receptor (EGFR) expression and epithelial markers (particularly cytokeratins (CK)) were the most commonly reported biomarkers (7/17) and immunohistochemical (IHC) staining was the most common technique for detection of biomarkers. The frequency of EGFR mutations was higher among women than men. Significantly elevated levels of CK-18 were observed in patients with squamous cell carcinoma and of CK-19 in patients with adenocarcinoma, squamous cell carcinoma, and NSCLC (P < 0.001). Prognostic or predictive role of cytokines and angiogenic markers as well as DNA expression were evaluated. The survey also showed that IHC was the most common technique for detection of biomarkers.
This systematic review and survey provides valuable information on biomarker usage in the Indian population, and highlights the need for initiatives required for future biomarker testing in India.
个性化医疗通过识别预测性和预后性生物标志物,提高了非小细胞肺癌(NSCLC)患者的管理水平,从而提升了检测效率和治疗效果。本系统评价和调查评估了生物标志物的使用模式、印度用于诊断NSCLC患者的分子检测技术以及癌症协会推荐的检测技术。
使用Cochrane系统评价方法中的相关检索策略,从Embase、PubMed和Cochrane数据库中检索过去12年的研究。感兴趣的结果包括NSCLC的生物标志物、生物标志物检测模式、诊断方法、指南以及生物标志物检测成本。
总共筛选出499项研究,17篇主要文献纳入本评价。表皮生长因子受体(EGFR)表达和上皮标志物(特别是细胞角蛋白(CK))是最常报道的生物标志物(7/17),免疫组织化学(IHC)染色是检测生物标志物最常用的技术。EGFR突变在女性中的发生率高于男性。在鳞状细胞癌患者中观察到CK-18水平显著升高,在腺癌、鳞状细胞癌和NSCLC患者中观察到CK-19水平显著升高(P<0.001)。评估了细胞因子和血管生成标志物以及DNA表达的预后或预测作用。调查还显示,IHC是检测生物标志物最常用的技术。
本系统评价和调查提供了有关印度人群生物标志物使用的有价值信息,并强调了印度未来生物标志物检测所需举措的必要性。